Figure 5: Efficacy of NLG207 and enzalutamide in castrated subcutaneous VCaP xenografted mice.

Castrated mice with subcutaneous VCaP xenografts were treated for 3 weeks with specified doses of vehicle control, enzalutamide, and/or NLG207, then monitored for tumor re-growth. Average percent change in tumor volume measurements (baseline at the start of treatment) through day 36 post-treatment initiation are summarized, with statistical significance of comparisons at specified time points denoted: * - p≤ 0.05 (A). Kaplan-Meier survival analysis progression-free survival (progression indicated when a tumor doubled in size) for each treatment group (B). Mice were censored if treatment resulted in >20% reduction in body weight. Average body weight measurements per treatment group collected following castration through 10 days post-drug treatment (C). The blue shading indicates the time frame for on-study drug treatment.